

## Special Issue

# Bioprospecting of Marine and Terrestrial Organisms for New Therapeutics

### Message from the Guest Editors

Bioprospecting for biologically active natural products is a well-known tool used in the early stages of drug discovery. The choice of a source for bioprospecting plays an important role in research efforts that is more likely to lead to new drugs. Unique ecosystems unexplored to date such as tundra, desert, salt marshes, and groundwater or mangrove forests are valuable sources of novel products. Advances in high-throughput omics technologies such as proteomics, genomics, and metabolomics have offered wide opportunities for bioprospecting and drug discovery, allowing thousands of molecules to be analyzed simultaneously. Marine ecosystems are an untapped reservoir of biodiversity with enormous potential for bioprospecting of pharmacologically active compounds. As of the updated Special Issue of *Biomedicines* named "Bioprospecting of Marine and Terrestrial Organisms for New Therapeutics", we would like to invite scientists who deal with marine or terrestrial bioprospecting to make a highly desirable contribution to nature-derived drug discovery.

- bioprospecting
- marine and terrestrial resources
- drug discovery
- natural products

### Guest Editors

Dr. Marina P. P. Isaeva

G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022 Vladivostok, Russia

Dr. Elena Leychenko

Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022 Vladivostok, Russia

### Deadline for manuscript submissions

closed (31 August 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/121667](https://mdpi.com/si/121667)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).